(Q41014662)

25 September 2017

title

The transition from first-line to second-line therapy in multiple sclerosis (English)

1 reference

25 September 2017

0 references

Friedemann Paul

2

0 references

author name string

Jan Dörr

series ordinal

1

1 reference

25 September 2017

publication date

1 June 2015

1 reference

Current treatment options in neurology

25 September 2017

published in

1 reference

25 September 2017

volume

17

1 reference

25 September 2017

issue

6

1 reference

25 September 2017

page(s)

354

1 reference

https://scigraph.springernature.com/pub.10.1007/s11940-015-0354-5

25 September 2017

exact match

0 references

cites work

Multiple sclerosis-a quiet revolution

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Assessment of system dysfunction in the brain through MRI-based connectomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Defining the clinical course of multiple sclerosis: the 2013 revisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Evidence for a two-stage disability progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Current evaluation of alemtuzumab in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

The current role of mitoxantrone in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Patient autonomy in multiple sclerosis--possible goals and assessment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Impact of multiple sclerosis relapses on progression diminishes with time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Scoring treatment response in patients with relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Freedom from disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Correlation of self-assessed fatigue and alertness in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Switching therapies in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Switching multiple sclerosis patients with breakthrough disease to second-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Infection risk in patients on multiple sclerosis therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Daclizumab (anti-CD25) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Treatment of pediatric multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Onset of secondary progressive phase and long-term evolution of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0354-5

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

12 December 2020

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

1 reference

12 December 2020

Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS

1 reference

12 December 2020

On the evaluation of disability in multiple sclerosis

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients

1 reference

12 December 2020

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

1 reference

12 December 2020

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

1 reference

12 December 2020

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

10.1007/S11940-015-0354-5

Identifiers

DOI

1 reference

Dimensions Publication ID

25 September 2017

1000190249

0 references

1 reference